WHO approves first malaria treatment for infants

The World Health Organization granted prequalification status to Coartem Baby (artemether-lumefantrine), the first antimalarial formulation specifically desi...

What Happened

The World Health Organization granted prequalification status to Coartem Baby (artemether-lumefantrine), the first antimalarial formulation specifically designed for newborns and young infants weighing between 2 and 5 kilograms.
The announcement, made on April 24, 2026, fills a critical gap — until now, infants with malaria were treated with formulations designed for older children, increasing risks of dosing errors, toxicity, and side effects.
WHO prequalification enables public sector procurement and international supply chains, making the drug accessible to around 30 million babies born each year in malaria-endemic areas of sub-Saharan Africa.
The drug was developed by Novartis in collaboration with Medicines for Malaria Venture (MMV) and is being made available on a largely not-for-profit basis in malaria-endemic regions.
The UN health agency simultaneously warned that progress against malaria is being undermined by drug resistance, insecticide resistance, diagnostic failures, and sharp reductions in foreign aid spending.

Static Topic Bridges

WHO Prequalification Programme

The WHO Prequalification Programme (PQP) assesses medicines, vaccines, diagnostics, and health products to ensure they meet international standards of quality, safety, and efficacy before they can be procured by UN agencies. Established in 1987 primarily for HIV/AIDS medicines, the programme has expanded to cover all essential medicines. Prequalification is a prerequisite for UNICEF and GAVI procurement, making it a powerful market-access lever for global health products.

WHO prequalification covers six product streams: medicines, vaccines, diagnostics, active pharmaceutical ingredients, finished pharmaceutical products, and medical devices.
The programme enables developing countries without robust domestic regulatory capacity to rely on WHO's technical assessment for procurement decisions.
India's Central Drugs Standard Control Organisation (CDSCO) is the national drug regulator — it grants approval separately from WHO PQ.

Connection to this news: WHO prequalifying Coartem Baby directly unlocks procurement by UNICEF, GAVI, and the Global Fund, potentially reaching the 30 million at-risk infants born annually in endemic zones.

Artemisinin Combination Therapy (ACT) and Drug Resistance

Artemisinin-based combination therapies (ACTs) have been the backbone of global malaria treatment since the early 2000s, recommended by WHO after chloroquine resistance became widespread. ACTs combine artemisinin (derived from the plant Artemisia annua) with a partner drug to eliminate parasites rapidly and reduce the chance of resistance developing. Partial artemisinin resistance — meaning the parasite survives initial drug exposure — has now been confirmed or suspected in at least 8 African countries, threatening the efficacy of the most effective malaria treatment class.

Artemisinin was discovered by Chinese scientist Tu Youyou, who was awarded the Nobel Prize in Physiology or Medicine in 2015 for this discovery.
Ganaplacide–Lumefantrine is a novel non-artemisinin combination therapy under development as a contingency against full artemisinin resistance.
Insecticide-resistant Anopheles stephensi mosquitoes have now invaded 9 African countries, posing additional vector-control challenges.

Connection to this news: The new infant formulation uses artemether-lumefantrine, an ACT — its development occurs against a backdrop of rising resistance to the very drug class it employs, making pipeline innovation and new diagnostic tests equally critical.

Malaria Burden in India

India is one of the highest-burden malaria countries in South-East Asia, accounting for the vast majority of cases in the region. The National Vector Borne Disease Control Programme (NVBDCP) under the Ministry of Health and Family Welfare coordinates malaria control nationally. India is committed to the WHO Global Technical Strategy (GTS) 2016–2030, which aims for a 90% reduction in malaria cases and deaths compared to 2015 levels.

Plasmodium falciparum (causes severe, potentially fatal malaria) and P. vivax (causes relapsing malaria) are the two major species infecting humans in India.
India's National Framework for Malaria Elimination (NFME) 2016–2030 targets malaria-free status by 2030.
Odisha, Jharkhand, Chhattisgarh, and Meghalaya account for the largest share of India's malaria burden.

Connection to this news: While this WHO approval primarily addresses sub-Saharan African infants, India's paediatric malaria challenge — especially in high-burden forested and tribal belt states — underscores why age-appropriate formulations are a global public health imperative.

Foreign Aid and Global Health Financing

International malaria control depends heavily on Official Development Assistance (ODA) from wealthy nations and multilateral donors such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, and USAID's President's Malaria Initiative (PMI). In 2024, total investment in malaria control globally was US$3.9 billion — less than half of the WHO's recommended US$9.3 billion annual target. A 21% decline in ODA flows has disrupted insecticide-treated net (ITN) distribution campaigns that were intended to protect 425 million people.

The Global Fund is the largest multilateral financier of malaria programmes.
In 2024, an estimated 282 million malaria cases and 610,000 deaths were recorded globally across 80 countries.
Africa accounts for 95% of malaria cases and deaths; children under five account for three-quarters of deaths.

Connection to this news: Even as the WHO approves a landmark new treatment, shrinking aid budgets threaten procurement and delivery capacity — highlighting the disconnect between scientific progress and health system access.

Key Facts & Data

Drug approved: Coartem Baby (artemether-lumefantrine) — first antimalarial for newborns and infants (2–5 kg)
Date of WHO prequalification: April 24, 2026
Developer: Novartis, in partnership with Medicines for Malaria Venture (MMV)
Target population: ~30 million babies born each year in malaria-endemic areas of Africa
Global malaria burden (2024): 282 million cases, 610,000 deaths across 80 countries
Africa's share: 95% of global malaria cases and deaths
Children under 5: Account for three-quarters of all malaria deaths in Africa
Artemisinin resistance: Confirmed or suspected in at least 8 African countries
ODA decline: ~21% fall in malaria-related foreign aid; only US$3.9 billion invested vs US$9.3 billion needed
Lives saved since 2000: 2.3 billion cases and 14 million deaths averted globally